At Epic Sciences, we are a data-driven organization, and we believe that data are the determinants of clinical utility. In our pursuit to impact patient care, we have invested in clinical research to understand the value of our CTC platform in addressing numerous scientific and clinical questions posed to us by oncologists, pathologist, drug developers, regulators and payors.
In January, we and our collaborators presented at:
- American Association for Cancer Research & Prostate Cancer Foundation Conference (AACR-PCF): Advances in Prostate Cancer Research
- American Society of Clinical Oncology Genitourinary (GU14) conference (Epic's GU14 press release).
These pages below provide an overview of data presented at these two conferences.
The discovery and relevance of novel CTC subtypes: implications of epithelial plasticity (CK-) and small CTCs on therapeutic response
Highly sensitive, single cell analysis: the importance of assessing the heterogeneity of cancer
Real-time tumor biopsying: towards a future of oncology pharmacodynamics (PD) monitoring and detection of aggressive transformation
Patient selection & predictive medicine from a tube of blood?
Snapshot of the Epic data presented at AACR-PCF and GU14 in January 2014
If you are interested in collaborating with us and would like to see more data, including the posters above, please contact us at [email protected].